Product Images Gemfibrozil

This text describes the frequency in percentage of gastrointestinal reactions and adverse events experienced by subjects who were administered either Gemfibrozil or a placebo. It reports the occurrence of dyspepsia, abdominal pain, acute appendicitis, and atrial fibrillation among others, in each group. The text also lists adverse events reported by more than 1% of subjects in both groups, which include diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation, and headache.*

The text is a chemical formula that represents a molecule composed of carbon, hydrogen, and oxygen atoms. It is not possible to determine the name or properties of the molecule with this limited information.*

This describes a table depicting CHD (coronary heart disease) rates in patients based on their baseline lipids. It shows the reduction in events per 1000 patients during years 0-5 of the Helsinki Heart Study. The patients are divided into different groups based on their lipid levels, including LDL-C (>175), HDL-C (>46.4, <35), and TG (>200). The table further shows incidence of events and the difference in rates between the placebo and gemfibrozil groups. The events refer to fatal and non-fatal myocardial infarctions and sudden cardiac deaths.*

The table presents the Cardiac Events and All-Cause Mortality occurring during the 3.5 Year Open-Label Follow-up to the Helsinki Heart Study with six open-label groups. The groups are identified first by the original randomization (P = placebo, G = Gemfibrozil) and then by the drug taken in the follow-up period. The table also provides the number of patients in each group.*

The table presents data from the Helsinki Heart Study, which analyzed the effect of gemfibrozil on cardiac events, deaths from cardiac and non-cardiac causes, and all-cause mortality. The study lasted 8.5 years and compared the outcomes of patients on gemfibrozil to those on a placebo. The table shows the number of events, the hazard ratios, and 95% confidence intervals. The intention-to-treat analysis was used, neglecting open-label treatment switches and exposure to study conditions. "Cardiac events" refers to fatal and non-fatal myocardial infarctions plus sudden cardiac deaths over the 8.5 year period.*